EP0855910A4 - Conjugues utiles pour traiter l'adenome prostatique benin - Google Patents
Conjugues utiles pour traiter l'adenome prostatique beninInfo
- Publication number
- EP0855910A4 EP0855910A4 EP96936504A EP96936504A EP0855910A4 EP 0855910 A4 EP0855910 A4 EP 0855910A4 EP 96936504 A EP96936504 A EP 96936504A EP 96936504 A EP96936504 A EP 96936504A EP 0855910 A4 EP0855910 A4 EP 0855910A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- benign prostatic
- prostatic hyperplasia
- conjugates useful
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US566495P | 1995-10-18 | 1995-10-18 | |
US5664P | 1995-10-18 | ||
GB9602903 | 1996-02-13 | ||
GBGB9602903.8A GB9602903D0 (en) | 1996-02-13 | 1996-02-13 | Conjugates useful in the treatment of benign prostatic hyperplasia |
PCT/US1996/016490 WO1997014416A1 (fr) | 1995-10-18 | 1996-10-15 | Conjugues utiles pour traiter l'adenome prostatique benin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0855910A1 EP0855910A1 (fr) | 1998-08-05 |
EP0855910A4 true EP0855910A4 (fr) | 2000-07-05 |
Family
ID=26308676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96936504A Withdrawn EP0855910A4 (fr) | 1995-10-18 | 1996-10-15 | Conjugues utiles pour traiter l'adenome prostatique benin |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0855910A4 (fr) |
JP (1) | JP2000506494A (fr) |
AU (1) | AU708475B2 (fr) |
WO (1) | WO1997014416A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU715632B2 (en) * | 1996-09-12 | 2000-02-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
HRP970566A2 (en) * | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
KR100580137B1 (ko) * | 1997-12-02 | 2006-05-16 | 머크 앤드 캄파니 인코포레이티드 | 전립선 암 치료에 유용한 접합체 및 이를 포함하는 약제학적 조성물 |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
MXPA01011502A (es) | 1999-05-14 | 2003-08-20 | Boehringer Ingelheim Pharma | Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas. |
US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
JP2003512475A (ja) * | 1999-10-27 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | 前立腺癌の治療に有用な複合体の塩形態 |
PL360826A1 (en) | 2000-03-15 | 2004-09-20 | Bristol-Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
GB0027552D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
GB0027551D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
AU2003233238A1 (en) * | 2002-05-10 | 2003-11-11 | Boehringer Ingelheim Pharma Gmbh And Co Kg | Fap-activated anti-tumor prodrugs |
CN116635054A (zh) | 2020-12-22 | 2023-08-22 | 科比欧尔斯公司 | 包括四肽部分的化合物 |
WO2022167664A1 (fr) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247792A2 (fr) * | 1986-05-27 | 1987-12-02 | Eli Lilly And Company | Conjugués d'immunoglobulines |
EP0282057A2 (fr) * | 1987-03-11 | 1988-09-14 | The Board Of Regents Of The University Of Michigan | Produits associés chémo-radio-immunologiques |
WO1992010212A1 (fr) * | 1990-12-05 | 1992-06-25 | Farmitalia Carlo Erba Srl | Conjugues d'anthracycline |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
SE9002480D0 (sv) * | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
-
1996
- 1996-10-15 WO PCT/US1996/016490 patent/WO1997014416A1/fr not_active Application Discontinuation
- 1996-10-15 EP EP96936504A patent/EP0855910A4/fr not_active Withdrawn
- 1996-10-15 AU AU74321/96A patent/AU708475B2/en not_active Ceased
- 1996-10-15 JP JP9515930A patent/JP2000506494A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247792A2 (fr) * | 1986-05-27 | 1987-12-02 | Eli Lilly And Company | Conjugués d'immunoglobulines |
EP0282057A2 (fr) * | 1987-03-11 | 1988-09-14 | The Board Of Regents Of The University Of Michigan | Produits associés chémo-radio-immunologiques |
WO1992010212A1 (fr) * | 1990-12-05 | 1992-06-25 | Farmitalia Carlo Erba Srl | Conjugues d'anthracycline |
Non-Patent Citations (3)
Title |
---|
LILJA ET AL.: "Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 89, May 1992 (1992-05-01), pages 4559 - 4563, XP002137094 * |
See also references of WO9714416A1 * |
TESSMER ET AL.: "Biological activity of prostate-specific antigen isolated...", ELECTROPHORESIS, vol. 16, no. 5, May 1995 (1995-05-01), pages 793 - 799, XP000901881 * |
Also Published As
Publication number | Publication date |
---|---|
JP2000506494A (ja) | 2000-05-30 |
EP0855910A1 (fr) | 1998-08-05 |
AU708475B2 (en) | 1999-08-05 |
WO1997014416A1 (fr) | 1997-04-24 |
AU7432196A (en) | 1997-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0926955A4 (fr) | Conjugues utiles dans le traitement du cancer de la prostate | |
NO993396L (no) | Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi | |
HK1024876A1 (en) | Conjugates useful in the treatment of prostate cancer | |
AU3011299A (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
EP0855910A4 (fr) | Conjugues utiles pour traiter l'adenome prostatique benin | |
AU1657097A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
PL340768A1 (en) | Conjugates useful in treating prostatic carcinoma | |
AP9901684A0 (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia | |
ZA982819B (en) | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. | |
HK1030776A1 (en) | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | |
ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
AU9128998A (en) | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis | |
EP0733365A3 (fr) | Utilisation des benzoquinolin-3-ones pour le traitement et la prévention du cancer de prostate | |
AU6570998A (en) | Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis | |
GB9602903D0 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
EP0748627A3 (fr) | Agonistes de la mélatonine pour l'utilisation dans le traitement d'hyperplasies prostatiques bénignes | |
ZA991319B (en) | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
EP1140906A4 (fr) | Imidazolones et leur utilisation dans le traitement de l'hyperplasie prostatique benigne et d'autres troubles | |
AU2002300904A1 (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia | |
ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. | |
AU2003204320A1 (en) | Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof | |
GB9626309D0 (en) | Conjugates useful in the treatment of prostate cancer | |
GB9624170D0 (en) | Conjugates useful in the treatment of prostate cancer | |
SI0942754T1 (en) | Conjugates useful in the treatment of prostate cancer | |
GB9810895D0 (en) | Combination therapy for the treatment of benign prostatic hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980518 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/40 A, 7A 61K 31/44 B, 7A 61K 31/70 B, 7A 61K 38/02 B, 7A 61K 38/07 B, 7A 61K 38/08 B, 7A 61K 38/10 B, 7A 61K 38/14 B, 7A 61K 47/48 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000522 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20031204 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040415 |